MBM, also known as 2,5-dimethoxy-4-butoxyamphetamine or as TMA2-4-BuO, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), MBM produced no effects at doses of up to 12 mg orally. Higher doses were not tested. As such, the properties and effects of MBM remain unknown. The drug is a potent full agonist of the serotonin 5-HT2A and 5-HT2C receptors (EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) = 26.9 nM (114%) and 57.4 nM (93%), respectively). Conversely, it is inactive as an agonist of the serotonin 5-HT2B and 5-HT1A receptors. The chemical synthesis of MBM has been described. MBM was first described in the literature by Shulgin in PiHKAL in 1991.
See also DOx (psychedelics) MEM § Derivatives Buscaline
References
External links MBM - Isomer Design


